Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a <i>Recombinant DNA Advisory Committee Symposium</i> Held June 15, 2010Hildegund C.J. Ertl, Scott E. Strome, John A. Zaia et al.|Cancer Research|2011Cited by 66
Evolving ethics, policy and reimbursement issues of vascularized composite allotransplantation: Symposium summaryJohn Rose, Wendy Dean, Carisa M. Cooney et al.|SAGE Open Medicine|2019Cited by 13
Data from Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a <i>Recombinant DNA Advisory Committee Symposium</i> Held June 15, 2010Hildegund C.J. Ertl, Scott E. Strome, John A. Zaia et al.|Unknown|2023Cited by 0
Supplementary References from Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a <i>Recombinant DNA Advisory Committee Symposium</i> Held June 15, 2010Hildegund C.J. Ertl, Scott E. Strome, John A. Zaia et al.|Unknown|2023Cited by 0
Supplementary Tables 1-5 from Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a <i>Recombinant DNA Advisory Committee Symposium</i> Held June 15, 2010Hildegund C.J. Ertl, Scott E. Strome, Jeffrey Kahn et al.|Unknown|2023Cited by 0